Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
出版年份 2020 全文链接
标题
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-06-09
DOI
10.1186/s13045-020-00896-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
- (2020) Henna Kasanen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy
- (2019) Jinyu Zhang et al. Journal for ImmunoTherapy of Cancer
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- Advanced stage melanoma therapies: Detailing the present and exploring the future
- (2018) Chelsea Luther et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
- (2018) Hansol Lee et al. OncoImmunology
- Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade
- (2017) Alejandro López-Soto et al. OncoImmunology
- Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients
- (2017) Cristina Maccalli et al. OncoImmunology
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Arginine dependence of tumor cells: targeting a chink in cancer’s armor
- (2016) M D Patil et al. ONCOGENE
- Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors
- (2015) S. Lu et al. CLINICAL CANCER RESEARCH
- Comparative genomics of the NKG2D ligand gene family
- (2015) Masanori Kasahara et al. IMMUNOLOGICAL REVIEWS
- Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype
- (2015) Gang Xiao et al. Journal of Hematology & Oncology
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
- (2015) Fahmin Basher et al. Oncotarget
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactive Oxygen Species– and DNA Damage Response–Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1
- (2014) Alessandra Soriani et al. JOURNAL OF IMMUNOLOGY
- Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention
- (2014) Aroa Baragaño Raneros et al. OncoImmunology
- Regulation of Ligands for the NKG2D Activating Receptor
- (2013) David H. Raulet et al. Annual Review of Immunology
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
- (2013) Y. Liao et al. BIOINFORMATICS
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
- (2013) Gang Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAR: ultrafast universal RNA-seq aligner
- (2012) Alexander Dobin et al. BIOINFORMATICS
- NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study
- (2012) Esther M de Kruijf et al. BMC CANCER
- Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells
- (2012) S.-H. Lee et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- IFN-γ production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice
- (2011) Kazuyoshi Takeda et al. JOURNAL OF LEUKOCYTE BIOLOGY
- ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients
- (2010) Roger W. McGilvray et al. INTERNATIONAL JOURNAL OF CANCER
- NKG2D Initiates Caspase-Mediated CD3 Degradation and Lymphocyte Receptor Impairments Associated with Human Cancer and Autoimmune Disease
- (2010) N. Hanaoka et al. JOURNAL OF IMMUNOLOGY
- The role of murine models of prostate cancer in drug target discovery and validation
- (2009) Imran Ahmad et al. Expert Opinion on Drug Discovery
- Soluble NKG2D ligands: prevalence, release, and functional impact
- (2008) Helmut Rainer Salih Frontiers in Bioscience-Landmark
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
- (2008) M. Jinushi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now